Nasdaq · Healthcare

Spero Therapeutics, Inc. (SPRO)

As-reported financials and recent SEC filings for Spero Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$66.8M

Net income

$8.6M

Net margin

12.8%

Diluted EPS

$0.15

ROE

14.5%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2024	FY2022	FY2021
Revenue	$66.8M	$48.0M	$103.8M	$53.5M	$18.3M
Gross profit	—	—	—	—	—
Operating income	$6.3M	$-73.4M	$21.5M	$-42.2M	$-88.0M
Net income	$8.6M	$-68.6M	$22.8M	$-46.4M	$-89.8M
Diluted EPS	$0.15	$-1.27	$0.43	$-1.23	$-2.91

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-25

42026-06-25

42026-06-25

42026-06-25

42026-06-25

42026-06-25

42026-06-25

8-K2026-06-25

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on SPRO

Search Spero Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.